Stock Scorecard
Stock Summary for Ligand Pharmaceuticals Inc - Class B (LGND) - $165.51 as of 9/16/2025 11:55:49 AM EST
Total Score
8 out of 30
Safety Score
53 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LGND
Positive Quarterly and Annual earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the Annual earnings growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LGND
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LGND
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LGND
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for LGND (53 out of 100)
Stock Price Rating (Max of 10) | 10 |
Historical Stock Price Rating (Max of 10) | 10 |
Stock Price Trend (Max of 10) | 7 |
Book Value (Max of 10) | 8 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 4 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 5 |
Trading Volume (Max of 10) | 5 |
Price to Earnings (Max of 10) | 0 |
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for LGND
Financial Details for LGND
Company Overview |
|
---|---|
Ticker | LGND |
Company Name | Ligand Pharmaceuticals Inc - Class B |
Country | USA |
Description | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California. |
Sector Name | HEALTHCARE |
Industry Name | BIOTECHNOLOGY |
Most Recent Quarter | 6/30/2025 |
Next Earnings Date | 11/5/2025 |
Stock Price History |
|
Last Day Price | 165.51 |
Price 4 Years Ago | 154.46 |
Last Day Price Updated | 9/16/2025 11:55:49 AM EST |
Last Day Volume | 315,460 |
Average Daily Volume | 272,636 |
52-Week High | 169.49 |
52-Week Low | 93.58 |
Last Price to 52 Week Low | 76.86% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 21.60 |
Sector PE | 41.00 |
5-Year Average PE | 21.79 |
Free Cash Flow Ratio | 13.17 |
Industry Free Cash Flow Ratio | 13.48 |
Sector Free Cash Flow Ratio | 29.67 |
Current Ratio Most Recent Quarter | 5.45 |
Total Cash Per Share | 12.57 |
Book Value Per Share Most Recent Quarter | 42.68 |
Price to Book Ratio | 3.90 |
Industry Price to Book Ratio | 29.02 |
Sector Price to Book Ratio | 32.08 |
Price to Sales Ratio Twelve Trailing Months | 17.23 |
Industry Price to Sales Ratio Twelve Trailing Months | 44.43 |
Sector Price to Sales Ratio Twelve Trailing Months | 19.62 |
Analyst Buy Ratings | 4 |
Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
Total Shares Outstanding | 19,494,500 |
Market Capitalization | 3,226,534,695 |
Institutional Ownership | 100.29% |
Dividends |
|
Ex-Dividend Date | 7/2/2010 |
Previous Dividend Amount | 0.0000 |
Current Dividend Amount | 0.4560 |
Total Years Dividend Increasing | 0 |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | -96.96% |
3-Year Dividend Growth Rate Percentage | -96.96% |
5-Year Dividend Growth Rate Percentage | -96.96% |
All-Time Dividend Growth Rate Percentage | -96.96% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 103.20% |
Annual Earnings Growth | -107.73% |
Reported EPS 12 Trailing Months | -4.04 |
Reported EPS Past Year | 2.93 |
Reported EPS Prior Year | 5.71 |
Net Income Twelve Trailing Months | -75,864,000 |
Net Income Past Year | -4,032,000 |
Net Income Prior Year | 52,154,000 |
Quarterly Revenue Growth YOY | 14.70% |
5-Year Revenue Growth | 6.80% |
Operating Margin Twelve Trailing Months | 20.40% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 245,020,000 |
Total Cash Past Year | 72,307,000 |
Total Cash Prior Year | 22,954,000 |
Net Cash Position Most Recent Quarter | 168,230,000 |
Net Cash Position Past Year | -4,388,000 |
Long Term Debt Past Year | 76,695,000 |
Long Term Debt Prior Year | 76,695,000 |
Total Debt Most Recent Quarter | 76,790,000 |
Equity to Debt Ratio Past Year | 0.92 |
Equity to Debt Ratio Most Recent Quarter | 0.92 |
Total Stockholder Equity Past Year | 830,439,000 |
Total Stockholder Equity Prior Year | 700,913,000 |
Total Stockholder Equity Most Recent Quarter | 828,529,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | 39,974,000 |
Free Cash Flow Per Share Twelve Trailing Months | 2.05 |
Free Cash Flow Past Year | 95,226,000 |
Free Cash Flow Prior Year | 46,056,000 |
Options |
|
Put/Call Ratio | 0.50 |
Has Options | Options Chain |
Liquidity Rating | None |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 6.34 |
MACD Signal | 7.06 |
20-Day Bollinger Lower Band | 83.72 |
20-Day Bollinger Middle Band | 131.17 |
20-Day Bollinger Upper Band | 178.62 |
Beta | 0.84 |
RSI | 67.53 |
50-Day SMA | 118.38 |
150-Day SMA | 89.23 |
200-Day SMA | 93.46 |
System |
|
Modified | 9/16/2025 3:50:24 AM EST |